Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC

作者：Yayi He, Linsong Chen, Lishu Zhao, Shiying Dang, Guifeng Liu, Shinji Sasada, C. Patrick, Nico van Zandwijk, Rafael Rosell, Helmut Popper, Hao Wang, Minlin Jiang, Haoyue Guo, Xinyi Liu, Shifu Chen, Xiaoni Zhang, Mingyan Xu, Bo Zhu, Ming Liu, Caicun Zhou · 发表于：Theranostics · 年份：2021 · DOI：10.7150/thno.58039 · 被引用次数：20 · 研究领域：Cancer Immunotherapy and Biomarkers、Immunotherapy and Immune Responses、Lung Cancer Treatments and Mutations

Our study presents an explanation for the unsatisfactory results of immunotherapy when given after chemotherapy, and suggests that first-line chemotherapy is able to influence the tumor microenvironment and decrease the efficacy of subsequent immunotherapy. The study was registered at ClinicalTrials.gov, number NCT03764917, and has completed enrolment; patients are still in follow-up.